Insiders · ACRV

ACRV insider transactions

Acrivon Therapeutics Inc. (ACRV) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.

Recent Form 3, 4, and 5 filings for ACRV

• 13d
  President and CEO Blume-Jensen Peter covered exercise/tax liability with 13,729 shares (SEC Form 4) to satisfy tax liability

  4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
• 19d
  Director Ra Capital Management, L.P. was granted 9,366 shares (SEC Form 4)

  4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
• 19d
  Director Shacham Sharon was granted 9,366 shares (SEC Form 4)

  4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
• 19d
  Director Tomsicek Michael John was granted 9,366 shares (SEC Form 4)

  4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
• 19d
  Director Palani Santhosh was granted 9,366 shares (SEC Form 4)

  4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
• 19d
  Director Magovcevic-Liebisch Ivana was granted 9,366 shares (SEC Form 4)

  4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
• 19d
  Director Dirocco Derek was granted 9,366 shares (SEC Form 4)

  4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
• 19d
  Director Baum Charles M was granted 9,366 shares (SEC Form 4)

  4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
• 19d
  Chief Accounting Officer Peterson Katharine was granted 14,227 shares, increasing direct ownership by 364% to 18,134 units (SEC Form 4)

  4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
• 19d
  Chief Medical Officer Mirza Mansoor Raza was granted 38,817 shares (SEC Form 4)

  4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
• 19d
  Chief Legal Officer Miller Mary was granted 49,830 shares, increasing direct ownership by 151% to 82,767 units (SEC Form 4)

  4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
• 19d
  Chief Financial Officer Levy Adam D. was granted 46,167 shares, increasing direct ownership by 220% to 67,150 units (SEC Form 4)

  4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
• 19d
  President and CEO Blume-Jensen Peter was granted 252,801 shares (SEC Form 4)

  4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
• 19d
  Chief Development Officer Gamelin Erick was granted 38,584 shares, increasing direct ownership by 268% to 52,992 units (SEC Form 4)

  4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
• 19d
  Chief Operating Officer Devroe Eric was granted 72,981 shares, increasing direct ownership by 99% to 146,953 units (SEC Form 4)

  4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
• 21d
  Chief Accounting Officer Peterson Katharine covered exercise/tax liability with 99 shares, decreasing direct ownership by 2% to 3,907 units (SEC Form 4) (for tax liability)

  4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
• 21d
  Chief Development Officer Gamelin Erick covered exercise/tax liability with 404 shares, decreasing direct ownership by 3% to 14,408 units (SEC Form 4) to cover taxes

  4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
• 21d
  Chief Legal Officer Miller Mary covered exercise/tax liability with 184 shares, decreasing direct ownership by 0.56% to 32,937 units (SEC Form 4) to cover taxes

  4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
• 21d
  Chief Operating Officer Devroe Eric covered exercise/tax liability with 613 shares, decreasing direct ownership by 0.82% to 73,972 units (SEC Form 4) (withholding obligation)

  4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
• 21d
  President and CEO Blume-Jensen Peter covered exercise/tax liability with 1,743 shares (SEC Form 4) (tax withholding)

  4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
• 46d
  Director Ra Capital Management, L.P. was granted 3,888,888 shares (SEC Form 4)

  4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
• 48d
  SEC Form 4 filed by Miller Mary

  4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
• 97d
  SEC Form 4 filed by Chief Accounting Officer Peterson Katharine

  4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
• 97d
  SEC Form 4 filed by Chief Legal Officer Miller Mary

  4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
• 97d
  SEC Form 4 filed by Chief Medical Officer Mirza Mansoor Raza

  4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
• 97d
  SEC Form 4 filed by Chief Financial Officer Levy Adam D.

  4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
• 97d
  SEC Form 4 filed by Chief Operating Officer Devroe Eric

  4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
• 97d
  SEC Form 4 filed by Chief Development Officer Gamelin Erick

  4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
• 97d
  SEC Form 4 filed by President and CEO Blume-Jensen Peter

  4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
• 104d
  President and CEO Blume-Jensen Peter covered exercise/tax liability with 14,265 shares (SEC Form 4)

  4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
• 110d
  Chief Accounting Officer Peterson Katharine covered exercise/tax liability with 116 shares, decreasing direct ownership by 3% to 4,006 units (SEC Form 4)

  4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
• 110d
  Chief Legal Officer Miller Mary covered exercise/tax liability with 217 shares, decreasing direct ownership by 0.64% to 33,679 units (SEC Form 4)

  4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
• 110d
  Chief Development Officer Gamelin Erick covered exercise/tax liability with 471 shares, decreasing direct ownership by 3% to 14,812 units (SEC Form 4)

  4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
• 110d
  Chief Operating Officer Devroe Eric covered exercise/tax liability with 723 shares, decreasing direct ownership by 0.96% to 74,585 units (SEC Form 4)

  4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
• 110d
  President and CEO Blume-Jensen Peter covered exercise/tax liability with 1,881 shares (SEC Form 4)

  4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
• 138d
  Chief Legal Officer Miller Mary covered exercise/tax liability with 659 shares, decreasing direct ownership by 2% to 33,896 units (SEC Form 4)

  4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
• 143d
  President and CEO Blume-Jensen Peter bought $82,124 worth of shares (49,000 units at $1.68) (SEC Form 4)

  4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
• 143d
  Chief Financial Officer Levy Adam D. bought $14,999 worth of shares (8,832 units at $1.70), increasing direct ownership by 73% to 20,983 units (SEC Form 4)

  4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
• 144d
  Chief Operating Officer Devroe Eric bought $17,218 worth of shares (10,000 units at $1.72), increasing direct ownership by 15% to 75,308 units (SEC Form 4)

  4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
• 195d
  President and CEO Blume-Jensen Peter covered exercise/tax liability with 19,904 shares (SEC Form 4)

  4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
• 202d
  Chief Accounting Officer Peterson Katharine covered exercise/tax liability with 99 shares, decreasing direct ownership by 2% to 4,122 units (SEC Form 4)

  4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
• 202d
  Chief Legal Officer Miller Mary covered exercise/tax liability with 184 shares, decreasing direct ownership by 0.53% to 34,555 units (SEC Form 4)

  4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
• 202d
  Chief Development Officer Gamelin Erick covered exercise/tax liability with 403 shares, decreasing direct ownership by 3% to 15,283 units (SEC Form 4)

  4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
• 202d
  Chief Operating Officer Devroe Eric covered exercise/tax liability with 613 shares, decreasing direct ownership by 0.93% to 65,308 units (SEC Form 4)

  4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
• 202d
  President and CEO Blume-Jensen Peter covered exercise/tax liability with 60,255 shares (SEC Form 4)

  4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
• 230d
  Chief Legal Officer Miller Mary covered exercise/tax liability with 558 shares, decreasing direct ownership by 2% to 34,739 units (SEC Form 4)

  4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
• 248d
  SEC Form 4 filed by Chief Medical Officer Mirza Mansoor Raza

  4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
• 248d
  Chief Legal Officer Miller Mary covered exercise/tax liability with 284 shares, decreasing direct ownership by 0.80% to 35,297 units (SEC Form 4)

  4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
• 287d
  President and CEO Blume-Jensen Peter covered exercise/tax liability with 19,905 shares (SEC Form 4)

  4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
• 294d
  Chief Accounting Officer Peterson Katharine covered exercise/tax liability with 99 shares, decreasing direct ownership by 2% to 4,221 units (SEC Form 4)

  4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
• 294d
  Chief Legal Officer Miller Mary covered exercise/tax liability with 184 shares, decreasing direct ownership by 0.51% to 35,581 units (SEC Form 4)

  4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
• 294d
  Chief Development Officer Gamelin Erick covered exercise/tax liability with 403 shares, decreasing direct ownership by 3% to 15,686 units (SEC Form 4)

  4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
• 294d
  Chief Operating Officer Devroe Eric covered exercise/tax liability with 613 shares, decreasing direct ownership by 0.92% to 65,921 units (SEC Form 4)

  4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
• 294d
  President and CEO Blume-Jensen Peter covered exercise/tax liability with 60,256 shares (SEC Form 4)

  4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
• 307d
  Chief Financial Officer Levy Adam D. covered exercise/tax liability with 1,164 shares, decreasing direct ownership by 9% to 12,151 units (SEC Form 4)

  4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
• 322d
  Chief Legal Officer Miller Mary covered exercise/tax liability with 558 shares, decreasing direct ownership by 2% to 35,765 units (SEC Form 4)

  4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
• 355d
  SEC Form 4 filed by Director Ra Capital Management, L.P.

  4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
• 356d
  SEC Form 4 filed by Director Dirocco Derek

  4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
• 356d
  SEC Form 4 filed by Director Tomsicek Michael John

  4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
• 356d
  SEC Form 4 filed by Director Shacham Sharon

  4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)